CAS: 849-55-8; Nylidrin Hydrochloride

该化合物是一种主要用作改善周边血液循环血管血管血管的抗药性抗药性β-肾性受体激动剂,其行动机制包括在血管中放松光滑肌肉组织,增加血液流到缺血地区,该化合物在治疗边缘血管紊乱和慢性隔离动脉疾病等条件方面的效力得到特别的注意.氢氯化尼利德表现出良好的生物利用率和有利的药用动能特征,确保了治疗效果的连贯性.其有据可查的安全特征和可靠的性能使它在临床环境中成为管理循环损伤的首选.盐的盐形式确保了制剂的稳定性和易用性.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

-2-bromo-1-propanone1-4-(benzyloxy)phenyl-2-bromo-1-propanone (RS)-1-methyl-3-phenylpropylamine 26H29NO2*ClHC26H29NO2*ClH

合成工艺路线路线简述

  • 合成目标产物 Nylidrin Hydrochloride 主要起始原料 4'-Benzyloxy-2-Bromopropiophenone And 2-Amino-4-Phenylbutane
  • (文献来源)合成步骤主要原料 4'-Benzyloxy-2-Bromopropiophenone 和 2-Amino-4-Phenylbutane
📜2-(4-Phenylbutan-2-Ylamino)-1-(4-Phenylmethoxyphenyl)Propan-1-One;Hydrochloride置于3% Pd/c,氢气体系中,用 甲醇 作为反应溶剂,以95%的收率获得产物布芬宁盐酸盐
参考文献:一种盐酸布酚宁的制备方法
标题:一种盐酸布酚宁的制备方法
摘要:本发明涉及一种盐酸布酚宁的制备方法,包括制备中间体iv和盐酸布酚宁.本发明方法操作简便,适合于工业化生产,产物纯度较高,质量达到人用药物制剂的使用标准.

海关参考信息

专利信息


专利号:US-8354116-B2
优先权日:2007-06-18
标题 :Bifunctional synthetic molecules
发明人:CARTER STEPHEN G; PATEL KANU; ZHU ZHEN; QIAO LIXIN
权利人:BIOCHEMICS INC; CARTER STEPHEN G; PATEL KANU; ZHU ZHEN; QIAO LIXIN
摘要:The synthesis and use of bifunctional molecules to improve the topical and transdermal delivery efficiency of various types of therapeutic agents or agents designed to promote the transdermal delivery of those therapeutic agents either into the skin tissue or into the systemic circulation. Three major classes of molecules are covalently joined as bifunctional substances; chemical vasodilators, passive dermal penetration enhancers and therapeutic or diagnostic drugs. Chemical vasodilators may be delivered into the skin to increasing the blood flow in a tissue that has compromised circulation or they may be used as part of a delivery vehicle to promote the delivery of the drug. Passive dermal penetration enhancers are those chemicals that promote the passive penetration of drugs and other chemicals through the stratum corneum and epidermis of the skin tissue. Drugs and diagnostic agents are the third group of chemicals that are candidates for the linkage of molecules.

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Broderick C, Forster R, Abdel-Hadi M, Salhiyyah K. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 2020 Oct 16;10(10):CD005262. doi: 10.1002/14651858.CD005262.pub4.
2: Jang Y, Shin JS, Lee JY, Shin H, Kim SJ, Kim M. In Vitro and In Vivo Antiviral Activity of Nylidrin by Targeting the Hemagglutinin 2-Mediated Membrane Fusion of Influenza A Virus. Viruses. 2020 May 25;12(5):581. doi: 10.3390/v12050581.
3: Salhiyyah K, Forster R, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 2015 Sep 29;9(9):CD005262. doi: 10.1002/14651858.CD005262.pub3. Update in: Cochrane Database Syst Rev. 2020 Oct 16;10:CD005262. doi: 10.1002/14651858.CD005262.pub4.

合成参考文献


摘要:Psychotropic Drugs and Related Compounds, 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972, -(351), 1972
摘要:Yakkyoku. Pharmacy., 24(431), 1973
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知